Biomarkers /
PD-L1
Back to Biomarkers List
Overview
Biomarker-Directed Therapies
PD-L1 is a predictive biomarker for use of pembrolizumab, atezolizumab, cemiplimab, ipilimumab, nab-paclitaxel, and nivolumab in patients.
Non-small cell lung carcinoma, breast carcinoma, cervical carcinoma, gastric carcinoma, and head and neck squamous cell carcinoma have the most therapies with PD-L1 as a predictive biomarker.
Of the therapies with PD-L1 as a predictive biomarker, 6 are FDA-approved in at least one clinical setting and 4 have NCCN guidelines in at least one clinical setting.
PD-L1 Overexpression, PD-L1 Expression (CPS >= 10), PD-L1 High Expression (TPS >= 1%), PD-L1 Low Expression (TPS >= 1%), and PD-L1 Expression (CPS >= 1) are the top alterations on PD-L1 targeted by therapies [4].
Atezolizumab +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Approved for the first-line treatment of adult patients with metastatic NSCLC with high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), with no EGFR or ALK alterations. |
Cemiplimab +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: For high expression of PD-L1 (Tumor Proportion Score >= 50%, clone 22C3) in the absence of EGFR/ALK/ROS1 (FDA/NCCN) and RET/BRAF V600E/MET Exon 14 Skipping (NCCN) mutations: recommended as a single agent for first-line therapy. |
Pembrolizumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated in combination with chemotherapy for patients with locally recurrent, unresectable, or metastatic TNBC whose tumors express PD-L1 [Combined Positive Score (CPS) >= 10]. |
Cervical Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Approved for recurrent or metastatic tumors expresssing PD-L1 [Combined Positive Score (CPS) >=1] with disease progression on or after chemotherapy. |
Gastric Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Approved for recurrent locally advanced or metastatic tumors expresssing PD-L1 [Combined Positive Score (CPS) >=1] with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy. |
Head And Neck Squamous Cell Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Approved as a single agent for the first line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1]. |
Malignant Esophageal Neoplasm -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for recurrent locally advanced or metastatic tumors expresssing PD-L1 [Combined Positive Score (CPS) >=1] with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy. |
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) | |
| Note: For low expression of PD-L1 (Tumor Proportion Score >= 1% and <50%, clone 22C3) in the absence of EGFR & ALK (FDA/NCCN) and ROS1, RET, BRAF V600E, and MET Exon 14 Skipping (NCCN) mutations: recommended as a single agent for first-line therapy (for patients with contraindications to combination chemotherapy, per NCCN), or as subsequent line with disease progression during or following appropriate systemic chemotherapy. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) | |
| Note: For high expression of PD-L1 (Tumor Proportion Score >= 50%, clone 22C3) in the absence of EGFR & ALK (FDA/NCCN) and ROS1, RET, BRAF V600E, and MET Exon 14 Skipping (NCCN) mutations: recommended as a single agent for first-line therapy, or as subsequent line with disease progression during or following appropriate systemic chemotherapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA) | |
| Note: For PD-L1 expressing tumors (Tumor Proportion Score >=1%, clone 22C3) with an EGFR or ALK alteration: FDA-approved as subsequent line of therapy following targeted therapy. However, per NCCN, data in the second-line setting suggest that subsequent pembrolizumab monotherapy is less effective in tumors with an EGFR mutation or ALK rearrangement. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: For PD-L1 expressing tumors (Tumor Proportion Score >=1%, clone 22C3) with a ROS1, RET, BRAF V600E, or MET Exon 14 Skipping alteration: approved as a single agent for first- or subsequent-line therapy. However, per NCCN, targeted therapy for the oncogenic driver should take precedence over an immune checkpoint inhibitor. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Second Line of Therapy (NICE, SMC) | |
| Note: Pembrolizumab is indicated as subsequent therapy for patients with NSCLC expressing CD274 (programmed death ligand 1 (PD-L1)), and whose disease has progressed on or after platinum-containing chemotherapy. An improved overall response rate was observed in CD274 (PD-L1) positive tumors. |
Atezolizumab + Nab-Paclitaxel +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells [IC] of any intensity covering ≥ 1% of the tumor area. |
Ipilimumab + Nivolumab +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must not match any of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA) | |
| Note: Approved as first-line treatment for patients with metastatic NSCLC whose tumors express PD-L1(≥1%), with no EGFR or ALK genomic tumor aberrations. |
Clinical Trials
PD-L1 status serves as an inclusion eligibility criteria in 186 clinical trials, of which 159 are open and 27 are closed. Of the trials that contain PD-L1 status as an inclusion criterion, 2 are early phase 1 (2 open), 41 are phase 1 (34 open), 20 are phase 1/phase 2 (18 open), 88 are phase 2 (73 open), 2 are phase 2/phase 3 (2 open), 31 are phase 3 (28 open), and 2 are phase 4 (2 open).
Trials with PD-L1 status in the inclusion eligibility criteria most commonly target non-small cell lung carcinoma, head and neck squamous cell carcinoma, adenocarcinoma of the gastroesophageal junction, gastric adenocarcinoma, and breast carcinoma [4].
The most frequent alterations to serve as inclusion eligibility criteria are PD-L1 High Expression, PD-L1 Expression, PD-L1 Low Expression, PD-L1 Expression (CPS >= 1), and PD-L1 Overexpression [4].
Pembrolizumab, atezolizumab, placebo, carboplatin, and nivolumab are the most frequent therapies in trials with PD-L1 as an inclusion criteria [4].
Significance of PD-L1 in Diseases
Non-Small Cell Lung Carcinoma +
PD-L1 is an inclusion criterion in 91 clinical trials for non-small cell lung carcinoma, of which 77 are open and 14 are closed. Of the trials that contain PD-L1 status and non-small cell lung carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 21 are phase 1 (19 open), 9 are phase 1/phase 2 (9 open), 39 are phase 2 (29 open), 19 are phase 3 (17 open), and 2 are phase 4 (2 open) [4].
Pembrolizumab, atezolizumab, cemiplimab, ipilimumab, and nivolumab have evidence of efficacy in patients with PD-L1 mutation in non-small cell lung carcinoma [4].
Head And Neck Squamous Cell Carcinoma +
PD-L1 is an inclusion criterion in 33 clinical trials for head and neck squamous cell carcinoma, of which 29 are open and 4 are closed. Of the trials that contain PD-L1 status and head and neck squamous cell carcinoma as inclusion criteria, 13 are phase 1 (12 open), 6 are phase 1/phase 2 (6 open), 13 are phase 2 (11 open), and 1 is phase 3 (0 open) [4].
Pembrolizumab has evidence of efficacy in patients with PD-L1 mutation in head and neck squamous cell carcinoma [4].
Breast Carcinoma +
PD-L1 is an inclusion criterion in 22 clinical trials for breast carcinoma, of which 18 are open and 4 are closed. Of the trials that contain PD-L1 status and breast carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 9 are phase 1 (9 open), 2 are phase 1/phase 2 (2 open), 9 are phase 2 (5 open), and 1 is phase 3 (1 open) [4].
Atezolizumab, nab-paclitaxel, and pembrolizumab have evidence of efficacy in patients with PD-L1 mutation in breast carcinoma [4].
Cervical Carcinoma +
PD-L1 is an inclusion criterion in 7 clinical trials for cervical carcinoma, of which 7 are open and 0 are closed. Of the trials that contain PD-L1 status and cervical carcinoma as inclusion criteria, 4 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].
Pembrolizumab has evidence of efficacy in patients with PD-L1 mutation in cervical carcinoma [4].
Gastric Carcinoma +
PD-L1 is an inclusion criterion in 6 clinical trials for gastric carcinoma, of which 5 are open and 1 is closed. Of the trials that contain PD-L1 status and gastric carcinoma as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 2 (1 open), and 1 is phase 3 (1 open) [4].
Pembrolizumab has evidence of efficacy in patients with PD-L1 mutation in gastric carcinoma [4].
Malignant Esophageal Neoplasm +
Pembrolizumab has evidence of efficacy in patients with PD-L1 mutation in malignant esophageal neoplasm [4].
Malignant Solid Tumor +
PD-L1 is an inclusion criterion in 32 clinical trials for malignant solid tumor, of which 28 are open and 4 are closed. Of the trials that contain PD-L1 status and malignant solid tumor as inclusion criteria, 20 are phase 1 (17 open), 7 are phase 1/phase 2 (6 open), and 5 are phase 2 (5 open) [4].
Adenocarcinoma Of The Gastroesophageal Junction +
PD-L1 is an inclusion criterion in 22 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 20 are open and 2 are closed. Of the trials that contain PD-L1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 10 are phase 1 (9 open), 3 are phase 1/phase 2 (3 open), 7 are phase 2 (6 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [4].
Gastric Adenocarcinoma +
PD-L1 is an inclusion criterion in 20 clinical trials for gastric adenocarcinoma, of which 18 are open and 2 are closed. Of the trials that contain PD-L1 status and gastric adenocarcinoma as inclusion criteria, 9 are phase 1 (8 open), 3 are phase 1/phase 2 (3 open), 6 are phase 2 (5 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [4].
Melanoma +
PD-L1 is an inclusion criterion in 17 clinical trials for melanoma, of which 14 are open and 3 are closed. Of the trials that contain PD-L1 status and melanoma as inclusion criteria, 8 are phase 1 (8 open), 1 is phase 1/phase 2 (0 open), 7 are phase 2 (5 open), and 1 is phase 4 (1 open) [4].
Non-Squamous Non-Small Cell Lung Carcinoma +
PD-L1 is an inclusion criterion in 17 clinical trials for non-squamous non-small cell lung carcinoma, of which 17 are open and 0 are closed. Of the trials that contain PD-L1 status and non-squamous non-small cell lung carcinoma as inclusion criteria, 4 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), 9 are phase 2 (9 open), and 3 are phase 3 (3 open) [4].
Urothelial Carcinoma +
PD-L1 is an inclusion criterion in 17 clinical trials for urothelial carcinoma, of which 14 are open and 3 are closed. Of the trials that contain PD-L1 status and urothelial carcinoma as inclusion criteria, 9 are phase 1 (7 open), 2 are phase 1/phase 2 (1 open), 5 are phase 2 (5 open), and 1 is phase 3 (1 open) [4].
Squamous Cell Lung Carcinoma +
PD-L1 is an inclusion criterion in 12 clinical trials for squamous cell lung carcinoma, of which 11 are open and 1 is closed. Of the trials that contain PD-L1 status and squamous cell lung carcinoma as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 5 are phase 2 (5 open), and 2 are phase 3 (2 open) [4].
Colorectal Carcinoma +
PD-L1 is an inclusion criterion in 9 clinical trials for colorectal carcinoma, of which 6 are open and 3 are closed. Of the trials that contain PD-L1 status and colorectal carcinoma as inclusion criteria, 6 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (0 open) [4].
Oropharyngeal Squamous Cell Carcinoma +
PD-L1 is an inclusion criterion in 9 clinical trials for oropharyngeal squamous cell carcinoma, of which 9 are open and 0 are closed. Of the trials that contain PD-L1 status and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 5 are phase 2 (5 open), and 1 is phase 2/phase 3 (1 open) [4].
Hypopharyngeal Squamous Cell Carcinoma +
PD-L1 is an inclusion criterion in 8 clinical trials for hypopharyngeal squamous cell carcinoma, of which 8 are open and 0 are closed. Of the trials that contain PD-L1 status and hypopharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (4 open), and 1 is phase 2/phase 3 (1 open) [4].
Laryngeal Squamous Cell Carcinoma +
PD-L1 is an inclusion criterion in 8 clinical trials for laryngeal squamous cell carcinoma, of which 8 are open and 0 are closed. Of the trials that contain PD-L1 status and laryngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (4 open), and 1 is phase 2/phase 3 (1 open) [4].
Oral Cavity Squamous Cell Carcinoma +
PD-L1 is an inclusion criterion in 8 clinical trials for oral cavity squamous cell carcinoma, of which 8 are open and 0 are closed. Of the trials that contain PD-L1 status and oral cavity squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (4 open), and 1 is phase 2/phase 3 (1 open) [4].
Renal Cell Carcinoma +
PD-L1 is an inclusion criterion in 8 clinical trials for renal cell carcinoma, of which 7 are open and 1 is closed. Of the trials that contain PD-L1 status and renal cell carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [4].
Bladder Carcinoma +
PD-L1 is an inclusion criterion in 5 clinical trials for bladder carcinoma, of which 4 are open and 1 is closed. Of the trials that contain PD-L1 status and bladder carcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 2 (1 open), and 1 is phase 3 (1 open) [4].
Ovarian Carcinoma +
PD-L1 is an inclusion criterion in 5 clinical trials for ovarian carcinoma, of which 4 are open and 1 is closed. Of the trials that contain PD-L1 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 2 (1 open) [4].
Small Cell Lung Carcinoma +
PD-L1 is an inclusion criterion in 5 clinical trials for small cell lung carcinoma, of which 5 are open and 0 are closed. Of the trials that contain PD-L1 status and small cell lung carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].
Bladder Urothelial Carcinoma +
PD-L1 is an inclusion criterion in 4 clinical trials for bladder urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PD-L1 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [4].
Clear Cell Renal Cell Carcinoma +
PD-L1 is an inclusion criterion in 4 clinical trials for clear cell renal cell carcinoma, of which 4 are open and 0 are closed. Of the trials that contain PD-L1 status and clear cell renal cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 2 (2 open) [4].
Esophageal Squamous Cell Carcinoma +
PD-L1 is an inclusion criterion in 4 clinical trials for esophageal squamous cell carcinoma, of which 4 are open and 0 are closed. Of the trials that contain PD-L1 status and esophageal squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Urethral Urothelial Carcinoma +
PD-L1 is an inclusion criterion in 4 clinical trials for urethral urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PD-L1 status and urethral urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [4].
Cervical Adenocarcinoma +
PD-L1 is an inclusion criterion in 3 clinical trials for cervical adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain PD-L1 status and cervical adenocarcinoma as inclusion criteria, 3 are phase 2 (3 open) [4].
Cervical Adenosquamous Carcinoma +
PD-L1 is an inclusion criterion in 3 clinical trials for cervical adenosquamous carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PD-L1 status and cervical adenosquamous carcinoma as inclusion criteria, 3 are phase 2 (3 open) [4].
Cervical Squamous Cell Carcinoma +
PD-L1 is an inclusion criterion in 3 clinical trials for cervical squamous cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PD-L1 status and cervical squamous cell carcinoma as inclusion criteria, 3 are phase 2 (3 open) [4].
Cutaneous Melanoma +
PD-L1 is an inclusion criterion in 3 clinical trials for cutaneous melanoma, of which 3 are open and 0 are closed. Of the trials that contain PD-L1 status and cutaneous melanoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [4].
Hepatocellular Carcinoma +
PD-L1 is an inclusion criterion in 3 clinical trials for hepatocellular carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PD-L1 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].
Invasive Breast Carcinoma +
PD-L1 is an inclusion criterion in 3 clinical trials for invasive breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PD-L1 status and invasive breast carcinoma as inclusion criteria, 3 are phase 2 (3 open) [4].
Merkel Cell Carcinoma +
PD-L1 is an inclusion criterion in 3 clinical trials for Merkel cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PD-L1 status and Merkel cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].
Pancreatic Adenocarcinoma +
PD-L1 is an inclusion criterion in 3 clinical trials for pancreatic adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain PD-L1 status and pancreatic adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [4].
Prostate Carcinoma +
PD-L1 is an inclusion criterion in 3 clinical trials for prostate carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PD-L1 status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Renal Pelvis Urothelial Carcinoma +
PD-L1 is an inclusion criterion in 3 clinical trials for renal pelvis urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PD-L1 status and renal pelvis urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [4].
Ureter Urothelial Carcinoma +
PD-L1 is an inclusion criterion in 3 clinical trials for ureter urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PD-L1 status and ureter urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [4].
Breast Adenocarcinoma +
PD-L1 is an inclusion criterion in 2 clinical trials for breast adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain PD-L1 status and breast adenocarcinoma as inclusion criteria, 2 are phase 3 (2 open) [4].
Cholangiocarcinoma +
PD-L1 is an inclusion criterion in 2 clinical trials for cholangiocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain PD-L1 status and cholangiocarcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [4].
Colorectal Adenocarcinoma +
PD-L1 is an inclusion criterion in 2 clinical trials for colorectal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain PD-L1 status and colorectal adenocarcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].
Diffuse Large B-Cell Lymphoma +
PD-L1 is an inclusion criterion in 2 clinical trials for diffuse large B-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain PD-L1 status and diffuse large B-cell lymphoma as inclusion criteria, 2 are phase 1 (1 open) [4].
Endometrial Carcinoma +
PD-L1 is an inclusion criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PD-L1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Esophageal Adenocarcinoma +
PD-L1 is an inclusion criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain PD-L1 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].
Fallopian Tube Carcinoma +
PD-L1 is an inclusion criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PD-L1 status and fallopian tube carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Gallbladder Carcinoma +
PD-L1 is an inclusion criterion in 2 clinical trials for gallbladder carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PD-L1 status and gallbladder carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [4].
Glioblastoma +
PD-L1 is an inclusion criterion in 2 clinical trials for glioblastoma, of which 2 are open and 0 are closed. Of the trials that contain PD-L1 status and glioblastoma as inclusion criteria, 2 are phase 1 (2 open) [4].
Head And Neck Carcinoma +
PD-L1 is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PD-L1 status and head and neck carcinoma as inclusion criteria, 2 are phase 1 (2 open) [4].
Hodgkin Lymphoma +
PD-L1 is an inclusion criterion in 2 clinical trials for hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain PD-L1 status and hodgkin lymphoma as inclusion criteria, 2 are phase 1 (1 open) [4].
Infiltrating Renal Pelvis And Ureter Urothelial Carcinoma +
PD-L1 is an inclusion criterion in 2 clinical trials for infiltrating renal pelvis and ureter urothelial carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PD-L1 status and infiltrating renal pelvis and ureter urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].
Lung Adenocarcinoma +
PD-L1 is an inclusion criterion in 2 clinical trials for lung adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain PD-L1 status and lung adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Lymphoma +
PD-L1 is an inclusion criterion in 2 clinical trials for lymphoma, of which 2 are open and 0 are closed. Of the trials that contain PD-L1 status and lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Mesothelioma +
PD-L1 is an inclusion criterion in 2 clinical trials for mesothelioma, of which 2 are open and 0 are closed. Of the trials that contain PD-L1 status and mesothelioma as inclusion criteria, 2 are phase 1 (2 open) [4].
Pancreatic Ductal Adenocarcinoma +
PD-L1 is an inclusion criterion in 2 clinical trials for pancreatic ductal adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain PD-L1 status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [4].
Primary Peritoneal Carcinoma +
PD-L1 is an inclusion criterion in 2 clinical trials for primary peritoneal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PD-L1 status and primary peritoneal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Prostate Adenocarcinoma +
PD-L1 is an inclusion criterion in 2 clinical trials for prostate adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain PD-L1 status and prostate adenocarcinoma as inclusion criteria, 2 are phase 2 (1 open) [4].
Skin Squamous Cell Carcinoma +
PD-L1 is an inclusion criterion in 2 clinical trials for skin squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PD-L1 status and skin squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Alveolar Rhabdomyosarcoma +
PD-L1 is an inclusion criterion in 1 clinical trial for alveolar rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and alveolar rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Alveolar Soft Part Sarcoma +
PD-L1 is an inclusion criterion in 1 clinical trial for alveolar soft part sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and alveolar soft part sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Ampulla Of Vater Carcinoma +
PD-L1 is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PD-L1 status and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Appendix Carcinoma +
PD-L1 is an inclusion criterion in 1 clinical trial for appendix carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and appendix carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Atypical Teratoid/Rhabdoid Tumor +
PD-L1 is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Basal Cell Carcinoma +
PD-L1 is an inclusion criterion in 1 clinical trial for basal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and basal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Biliary Tract Carcinoma +
PD-L1 is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and biliary tract carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Carcinoma Of Unknown Primary +
PD-L1 is an inclusion criterion in 1 clinical trial for carcinoma of unknown primary, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and carcinoma of unknown primary as inclusion criteria, 1 is phase 1 (1 open) [4].
Childhood Central Nervous System Embryonal Carcinoma +
PD-L1 is an inclusion criterion in 1 clinical trial for childhood central nervous system embryonal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and childhood central nervous system embryonal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Classical Hodgkin Lymphoma +
PD-L1 is an inclusion criterion in 1 clinical trial for classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Desmoplastic Small Round Cell Tumor +
PD-L1 is an inclusion criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Diffuse Intrinsic Pontine Glioma +
PD-L1 is an inclusion criterion in 1 clinical trial for diffuse intrinsic pontine glioma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and diffuse intrinsic pontine glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Distal Bile Duct Carcinoma +
PD-L1 is an inclusion criterion in 1 clinical trial for distal bile duct carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PD-L1 status and distal bile duct carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Embryonal Rhabdomyosarcoma +
PD-L1 is an inclusion criterion in 1 clinical trial for embryonal rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and embryonal rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Embryonal Tumor With Multilayered Rosettes, C19MC-Altered +
PD-L1 is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Ependymoma +
PD-L1 is an inclusion criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and ependymoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Esophageal Carcinoma +
PD-L1 is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Of Bone +
PD-L1 is an inclusion criterion in 1 clinical trial for Ewing sarcoma/peripheral primitive neuroectodermal tumor of bone, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and Ewing sarcoma/peripheral primitive neuroectodermal tumor of bone as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Follicular Lymphoma +
PD-L1 is an inclusion criterion in 1 clinical trial for follicular lymphoma, of which 0 are open and 1 is closed. Of the trial that contains PD-L1 status and follicular lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].
High Grade Ovarian Serous Adenocarcinoma +
PD-L1 is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Infiltrating Bladder Urothelial Carcinoma +
PD-L1 is an inclusion criterion in 1 clinical trial for infiltrating bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and infiltrating bladder urothelial carcinoma as inclusion criteria, 1 is phase 3 (1 open) [4].
Intrahepatic Cholangiocarcinoma +
PD-L1 is an inclusion criterion in 1 clinical trial for intrahepatic cholangiocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains PD-L1 status and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Large Cell Lung Carcinoma +
PD-L1 is an inclusion criterion in 1 clinical trial for large cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and large cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Liver And Intrahepatic Bile Duct Carcinoma +
PD-L1 is an inclusion criterion in 1 clinical trial for liver and intrahepatic bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and liver and intrahepatic bile duct carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Malignant Glioma +
PD-L1 is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and malignant glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Malignant Mesothelioma +
PD-L1 is an inclusion criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Pleural Mesothelioma +
PD-L1 is an inclusion criterion in 1 clinical trial for malignant pleural mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and malignant pleural mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].
Mediastinal Large B-Cell Lymphoma +
PD-L1 is an inclusion criterion in 1 clinical trial for mediastinal large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains PD-L1 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Medulloblastoma +
PD-L1 is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and medulloblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Mucosal Melanoma +
PD-L1 is an inclusion criterion in 1 clinical trial for mucosal melanoma, of which 0 are open and 1 is closed. Of the trial that contains PD-L1 status and mucosal melanoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Multiple Myeloma +
PD-L1 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 0 are open and 1 is closed. Of the trial that contains PD-L1 status and multiple myeloma as inclusion criteria, 1 is phase 1 (0 open) [4].
Myelodysplastic Syndromes +
PD-L1 is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 0 are open and 1 is closed. Of the trial that contains PD-L1 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (0 open) [4].
Nasopharyngeal Carcinoma +
PD-L1 is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Neuroblastoma +
PD-L1 is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Neuroendocrine Tumor +
PD-L1 is an inclusion criterion in 1 clinical trial for neuroendocrine tumor, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and neuroendocrine tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Non-Hodgkin Lymphoma +
PD-L1 is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains PD-L1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Oropharyngeal Carcinoma +
PD-L1 is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Ovarian Endometrioid Adenocarcinoma +
PD-L1 is an inclusion criterion in 1 clinical trial for ovarian endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and ovarian endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Pancreatic Carcinoma +
PD-L1 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Peripheral T-Cell Lymphoma, Not Otherwise Specified +
PD-L1 is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and peripheral T-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [4].
Peritoneal Malignant Mesothelioma +
PD-L1 is an inclusion criterion in 1 clinical trial for peritoneal malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and peritoneal malignant mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].
Pleural Biphasic Mesothelioma +
PD-L1 is an inclusion criterion in 1 clinical trial for pleural biphasic mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and pleural biphasic mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].
Pleural Epithelioid Mesothelioma +
PD-L1 is an inclusion criterion in 1 clinical trial for pleural epithelioid mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and pleural epithelioid mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].
Pleural Mesothelioma, Sarcomatoid Type +
PD-L1 is an inclusion criterion in 1 clinical trial for pleural mesothelioma, sarcomatoid type, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and pleural mesothelioma, sarcomatoid type as inclusion criteria, 1 is phase 1 (1 open) [4].
Primary Mediastinal B-Cell Lymphoma +
PD-L1 is an inclusion criterion in 1 clinical trial for primary mediastinal B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and primary mediastinal B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Renal Pelvis And Ureter Urothelial Carcinoma +
PD-L1 is an inclusion criterion in 1 clinical trial for renal pelvis and ureter urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and renal pelvis and ureter urothelial carcinoma as inclusion criteria, 1 is phase 3 (1 open) [4].
Rhabdoid Tumor +
PD-L1 is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Squamous Cell Carcinoma +
PD-L1 is an inclusion criterion in 1 clinical trial for squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Squamous Cell Carcinoma Of Unknown Primary +
PD-L1 is an inclusion criterion in 1 clinical trial for squamous cell carcinoma of unknown primary, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and squamous cell carcinoma of unknown primary as inclusion criteria, 1 is phase 2 (1 open) [4].
Synovial Sarcoma +
PD-L1 is an inclusion criterion in 1 clinical trial for synovial sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and synovial sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Transitional Cell Carcinoma +
PD-L1 is an inclusion criterion in 1 clinical trial for transitional cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and transitional cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Undifferentiated Pleomorphic Sarcoma +
PD-L1 is an inclusion criterion in 1 clinical trial for undifferentiated pleomorphic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and undifferentiated pleomorphic sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Wilms Tumor +
PD-L1 is an inclusion criterion in 1 clinical trial for Wilms tumor, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 status and Wilms tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
